Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study by Arpino, Grazia et al.
Nab-paclitaxel for the management of triple-negative
metastatic breast cancer: a case study
Grazia Arpino, Sabino De Placido and Carmine De Angelis
The optimal sequence of systemic chemotherapy in
metastatic breast cancer (MBC) is unknown. We report the
case of a woman who was successfully treated with
nanoparticle albumin-bound (nab)-paclitaxel for triple
negative MBC in our institution. In November 2008,
a 48-year-old woman underwent surgical treatment
for a triple negative invasive ductal breast cancer
and subsequently received adjuvant chemotherapy
with fluorouracil/epirubicin/cyclophosphamide and
radiotherapy. Sixteen months after surgery, she presented
with a left chest wall metastatasis. The patient received
combination therapy with conventional paclitaxel
(90mg/m² weekly for 3 out of 4 weeks [QW 3/4]) and
bevacizumab (10mg/kg every 2 weeks [Q2W]) as first-line
treatment for MBC (six cycles; March to September 2010)
and achieved a partial response at the metastatic site.
Bevacizumab monotherapy was continued until disease
progression (April 2011) with the development of a single
infraclavicular lymph node metastasis and an increase in
the dimensions of the left chest wall lesion. From May
to December 2011, the patient received nab-paclitaxel
260mg/m² every 3 weeks (Q3W) as second-line treatment
(11 cycles). After three cycles, the left chest wall lesion
and the infraclavicular lymph node metastasis were
undetectable and the patient was considered to have
achieved a complete response. Treatment was well
tolerated with no significant toxicity or need for dose
reduction. Given our case, here we review the clinical
evidence and discuss the potential role of nab-paclitaxel for
the treatment of triple negative MBC, a subgroup typically
characterized as having aggressive disease and limited
treatment options. Anti-Cancer Drugs 26:117–122 © 2014
Wolters Kluwer Health | Lippincott Williams & Wilkins.
Anti-Cancer Drugs 2015, 26:117–122
Keywords: breast cancer, metastatic, nab-paclitaxel, prognostic factors,
triple negative
Department of Clinical Medicine, Division of Medical Oncology, University of
Naples Federico II, Naples, Italy
Correspondence to Grazia Arpino, MD, PhD, Department of Clinical Medicine,
Division of Medical Oncology, University of Naples Federico II, Pansini 5,
80131, Naples, Italy
Tel: + 39 081 7463772; fax: + 39 081 2203147; e-mail: grazia.arpino@unina.it
Received 22 April 2014 Revised form accepted 18 June 2014
Introduction
Despite advances in screening and treatment, breast
cancer remains a leading cause of death among women
worldwide [1]. Approximately 15–20% of patients with
breast cancer have triple-negative (TN) breast tumors
[i.e. no estrogen receptor (ER), progesterone receptor
(PgR), or human epidermal growth factor receptor-2
(HER2) expression]. For these patients, no targeted
therapy is available and chemotherapy remains the sys-
temic treatment of choice.
TN tumors are usually more aggressive and associated
with worse survival compared with non-TN tumors [2–4].
Effective and fast-acting chemotherapy is therefore
required, although the optimal treatment approach
remains controversial. Some suggest that cyclopho-
sphamide is a necessary component of adjuvant che-
motherapy, and advocate approaches such as dose-dense
cyclophosphamide/methotrexate/fluorouracil or six cycles
of fluorouracil/epirubicin/cyclophosphamide (FEC) [5].
Others suggest than TN tumors should not be treated
with anthracyclines as they are topoisomerase 2-negative
and HER2-negative [6]. In the neoadjuvant setting,
anthracycline/taxane regimens have resulted in a high
pathological complete response rate in TN disease [7].
Platinum agents are also considered to be particularly
effective, especially in TN tumors with BRCA mutations
[8]. However, the literature is conflicting, and promising
results have also been reported for other regimens, such
as dose-dense epirubicin plus cyclophosphamide, fol-
lowed by docetaxel [9].
The use of chemotherapy in metastatic breast cancer
(MBC) has been studied extensively, and a broad spectrum
of agents are now available (Table 1) [10]. Current guide-
lines suggest that as patients with metastatic triple negative
breast cancer (mTNBC) frequently have visceral involve-
ment, aggressive disease, and/or a risk of rapid deterioration,
combination chemotherapy may be preferred [11].
However, whether this offers an advantage over sequential
therapy is an unsettled issue as results from clinical trials are
conflicting. Currently, taxane-based regimens are the only
standard of care first-line therapy for patients who have
received anthracycline-based adjuvant therapy [11].
However, the considerable toxicity profile of traditional
taxanes (i.e. conventional paclitaxel and docetaxel) limits
their suitability for some patients, and cumulative toxicity
associated with long-term use is a major limitation for many
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more patients. A significant proportion of patients receiving
traditional taxanes require treatment interruptions, delays,
and/or discontinuations because of toxicity, and although
premedication (corticosteroids, antihistamines, H2 antago-
nists, and granulocyte colony-stimulating factor) can ame-
liorate many toxicities, the use of these agents, especially
long term, remains challenging [12].
Nanoparticle albumin-bound (nab)-paclitaxel (Abraxane;
Celgene Corporation, Summit, New Jersey, USA) is a next-
generation taxane that does not include a solvent. This
reduces the risk of hypersensitivity reactions and eliminates
the need for steroids and antihistamine premedication [13].
The absence of a solvent and the presence of albumin in
nab-paclitaxel allow higher doses of paclitaxel to be deliv-
ered compared with traditional taxanes as drug transport to
the tumor is considered to be enhanced by albumin
receptor (gp60)-mediated transcytosis [14] and by albumin
binding to proteins such as SPARC (secreted protein,
acidic, and rich in cysteine) at the site of the tumor [15].
Table 1 Available chemotherapy agents/regimens for metastatic breast cancer recommended by the NCCN [10]
Agent Dosing schedule
Single agents
Doxorubicin 60-75 mg/m2 i.v. day 1 cycled every 21 days or 20 mg/m2 i.v. day 1 weekly
Pegylated liposomial encapsulated
doxorubicin
50 mg/m2 i.v. day 1 cycled every 28 days
Paclitaxel 175 mg/m2 i.v. day 1 every 21 days or
80 mg/m2 i.v. day 1 weekly
Capecitabine 1000-1250 mg/m2 PO twice daily on days 1-14 cycled every 28 days
Gemcitabine 800-1200 mg/m2 i.v. on days 1, 8, 15 cycled every 28 days
Cisplatin 75 mg/m2 i.v. on day 1 cycled every 21 days
Vinorelbine 25mg/m2 i.v. day 1 weekly
Cyclophosphamide 50 mg PO daily on days 1-21 cycled every 28 days
Carboplatin AUC6 on day 1 cycled every 21-28 days
Nab-paclitaxel 100 mg/m2 or 150 mg/m2 i.v. days 1, 8, 15 every 28 days or
260 mg/m2 i.v. cycled every 21 days
Epirubicin 60-90 mg/m2 i.v. on day 1 cycled every 21 days
Ixabepilone 40 mg/m2 i.v. on day 1 cycled every 21 days
Eribulin 1.4 mg/m2 i.v. days 1, 8 cycled every 21 days
Docetaxel 60-100 mg/m2 i.v. day 1 cycled every 21 days or
40 mg/m2 i.v. weekly for 6 weeks, followed by a 2-week rest, then repeat
Combination therapy
Docetaxel/capecitabine Docetaxel 75 mg/m2 i.v. day 1
Capecitabine 950 mg/m2 PO twice daily days 1-14
Cycled every 21 days
GT Paclitaxel 175 mg/m2 i.v. day 1
Gemcitabine 1250mg/m2 i.v. days 1, 8
Cycled every 21 days
Paclitaxel/bevacizumab Paclitaxel 90 mg/m2 i.v. day 1, 8, 15
Bevacizumab 10 mg/kg i.v. days 1, 15
Cycled every 28 days
Gemcitabine/carboplatin Gemcitabine 1000 mg/m2 on days 1, 8
Carboplatin AUC2 i.v. on days 1, 8
Cycled every 21 days
CAF Cyclophosphamide 100 mg/m2 PO days 1-14
Doxorubicin 30mg/m2 i.v. days 1, 8
5-fluorouracil 500 mg/m2 i.v. days 1, 8
Cycled every 28 days
FAC 5-fluorouracil 500 mg/m2 i.v. days 1, 8 or days 1, 4
Doxorubicin 50mg/m2 i.v. days 1
Cyclophosphamide 500 mg/m2 i.v. days 1
Cycled every 21 days
FEC 5-fluorouracil 500 mg/m2 i.v. days 1, 8
Epirubicin 50 mg/m2 i.v. days 1, 8
Cyclophosphamide 100 mg/m2 PO days 1-14
Cycled every 28 days
AC Doxorubicin 60mg/m2 i.v. days 1
Cyclophosphamide 600 mg/m2 i.v. days 1
Cycled every 21 days
EC Epirubicin 75 mg/m2 i.v. days 1
Cyclophosphamide 600 mg/m2 i.v. days 1
Cycled every 21 days
CMF Cyclophosphamide 100 mg/m2 PO days 1-14
Methotrexate 40 mg/m2 i.v. days 1, 8
5-fluorouracil 600 mg/m2 i.v. days 1, 8
Cycled every 28 days
AC, doxorubicin/cyclophosphamide; AUC, area under the concentration-time curve; CAF, cyclophosphamide/doxorubicin/5-fluorouracil; CMF, cyclophosphamide/
methotrexate/5-fluorouracil; EC, epirubicin/cyclophosphamide; FAC, 5-fluorouracil/doxorubicin/cyclophosphamide; FEC, 5-fluorouracil/epirubicin/cyclophosphamide;
GT, gemcitabine/paclitaxel; i.v., intravenous; MBC, metastatic breast cancer; NCCN, National Comprehensive Cancer Network; PO, per os.
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The clinical benefits of nab-paclitaxel in MBC were
reported in a large Phase III study which showed that,
compared with conventional paclitaxel 175 mg/m2 admi-
nistered every 3 weeks (Q3W), nab-paclitaxel 260 mg/m2
Q3W was associated with a higher objective response rate
(33 vs. 19%, P= 0.001) and prolonged progression-free
survival (22.7 vs. 16.6 weeks, P= 0.003) [12,16], and an
improvement in median overall survival (OS) in patients
who received nab-paclitaxel as greater than first-line
therapy (56.4 vs. 46.7 weeks, P= 0.024) [16]. Nab-
paclitaxel was also associated with a rapid and dramatic
tumor response (shrinkage), with maximum response to
nab-paclitaxel occurring by cycle 3 in 91% of responding
patients [16]. As expected with a 49% higher paclitaxel
dose, treatment with nab-paclitaxel resulted in a higher
incidence of grade 3 sensory neuropathy compared with
conventional paclitaxel (10 vs. 2%, P< 0.001). However,
time to improvement of sensory neuropathy from grade 3
to grade ≤ 2 was more rapid with nab-paclitaxel (22 vs.
79 days) [12,16].
Findings from this Phase III study led to the regulatory
approval of nab-paclitaxel 260 mg/m2 Q3W for the treat-
ment of MBC. In Europe, it is licensed for use in adult
patients who have failed first-line treatment for meta-
static disease and for whom standard, anthracycline-
containing therapy is not indicated [13].
The superior therapeutic index of nab-paclitaxel over
traditional taxanes could make it a particularly attractive
treatment for many patients with MBC, including those
with mTNBC. However, there is a dearth of data
describing its use in clinical practice. Here, we describe a
clinical case of a patient with mTNBC who received nab-
paclitaxel as second-line therapy for metastatic disease.
Case presentation
A 48-year-old white woman was diagnosed with early
breast cancer in November 2008. She immediately
underwent a left quadrantectomy with axillary lymph
node dissection for a pT2 (2.1 cm) invasive ductal carci-
noma. Histology showed that the disease was pN0 and
poorly differentiated. Hormonal receptor status (ER and
PgR) was negative, HER2 was not overexpressed, and
Ki-67 was 40%. The patients received six cycles of
adjuvant FEC (completed June 2009), followed by left
breast irradiation.
Sixteen months after surgery, a left chest wall metastasis
was detected that was histologically verified as ER
negative, PR negative, HER2 1+ , and Ki-67 30%. The
patient was referred for surgery, but the lesion was con-
sidered inoperable as it was infiltrating the pectoral
muscle. The patient received conventional paclitaxel
[90 mg/m2 weekly for 3 of 4 weeks (QW 3/4)] plus bev-
acizumab [10 mg/kg every 2 weeks (Q2W)] as a first-line
treatment for MBC, with a total of six cycles
administered between March and September 2010.
Treatment resulted in a partial response at the
metastatic site.
In September 2010, conventional paclitaxel was dis-
continued because of grade 4 neurologic toxicity.
Bevacizumab was continued as monotherapy until April
2011, when an increase in the left chest wall lesion
dimensions was detected along with a single infra-
clavicular lymph node metastasis (Fig. 1a). As the patient
had received six cycles of epirubicin as part of her adju-
vant therapy and developed relapse after 9 months, she
was considered anthracycline resistant. Nab-paclitaxel
260 mg/m2 Q3W was therefore selected as the most
appropriate second-line treatment. After three cycles, the
left chest wall lesion and the infraclavicular lymph node
Fig. 1
(a)
(b)
Computed tomography imaging of a 48-year-old patient with metastatic
breast cancer at progression following first-line treatment with six cycles
of conventional paclitaxel 90 mg/m2 QW 3/4 plus bevacizumab 10mg/
kg Q2W for 12 months (a) and then after the first three cycles of
second-line treatment with nab-paclitaxel 260mg/m2 Q3W (b). Arrows
show the extent of the left chest wall lesion before and after nab-
paclitaxel therapy. Q2W, every 2 weeks; Q3W, every 3 weeks; QW 3/4,
weekly for 3 weeks of a 4 week cycle.
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metastasis were undetectable (Fig. 1b), and the patient
was considered to have achieved a complete response
according to Response Evaluation Criteria for Solid
Tumors [17]. Nab-paclitaxel was continued at the same
dose from May to December 2011 (11 cycles).
Importantly, treatment was well tolerated, with no sig-
nificant toxicity or need for dose reduction. The principal
toxicities were mild sensory neuropathy and grade 2
fatigue. No febrile neutropenia was noted.
In July 2012, the patient experienced disease progression
at the previously described metastatic sites. Subsequent
treatments, including gemcitabine (1000 mg/m2 QW 2/3)
plus carboplatin (AUC5 on day 1 Q3W), pegylated lipo-
somal doxorubicin (50 mg/m2 every 4 weeks), and
vinorelbine (25 mg/m2 QW), all yielded poor results. In
May 2013, further disease progression resulted in general
deterioration and the patient received best
supportive care.
Discussion
MBC remains an incurable disease with a poor prognosis
and a median 5-year survival of only 23–26% [18,19]. As
such, effective long-term management of MBC poses
significant clinical challenges, and more effective and
better tolerated agents are urgently needed [11]. For
patients with mTNBC, the lack of biomarkers to predict
chemotherapy responsiveness or a consensus on the best
agents to use mean that clinical judgment of the potential
risk and benefit is the principal factor driving the physi-
cian’s choice of which chemotherapy to administer.
The patient presented in this clinical case had very
aggressive early breast cancer, relapsing after less than
1 year of completing adjuvant chemotherapy. She
experienced an excellent tumor response to first-line
taxane chemotherapy, but had to discontinue conven-
tional paclitaxel after six cycles because of unbearable
neurotoxicity that significantly limited her quality of life.
However, on the basis of her apparent sensitivity to
taxane therapy, nab-paclitaxel was chosen as her second-
line treatment, and despite having aggressive disease, our
patient achieved a prolonged period of response with
minimal and acceptable toxicities.
The decision to treat this patient with nab-paclitaxel is
supported by the superior therapeutic index of this agent
shown in the large Phase III trial [16]. Emerging data
from Phase II studies and retrospective analyses also
suggest that nab-paclitaxel may be effective as part of
combination therapy in patients with mTNBC [20,21]
and in those who have received taxane previously [22,23]
as it does not show cross-resistance with conventional
paclitaxel or docetaxel, even in heavily pretreated
patients [22]. In addition, findings from a recent post-hoc
analysis of data from the Phase III study indicate that
nab-paclitaxel is associated with improved efficacy in
subgroups of patients with characteristics typical of
aggressive disease, such as those with at least three
metastatic lesions, visceral-dominant metastases, and
patients with a short disease-free interval [24–26]. For
patients receiving study treatment as greater than first-
line therapy, i.e. the patient subgroup for whom nab-
paclitaxel is currently licensed in MBC, nab-paclitaxel
was associated with a significant improvement in OS in
patients with at least three metastatic lesions (hazard ratio
0.71, P= 0.037; Fig. 2a) and a trend toward improved OS
Fig. 2
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Kaplan–Meier curve of overall survival in patients with metastatic breast
cancer who received treatment with nab-paclitaxel or conventional
paclitaxel as greater than first-line therapy in the randomized Phase III
study. (a) Patients with at least three metastases (HR=0.71;
P=0.037). (b) Patients with visceral-dominant disease (P=0.145) [16,
24]. HR, hazard ratio; Q3W, every 3 weeks.
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in those with visceral-dominant disease (P= 0.145;
Fig. 2b) [24]. As patients with mTNBC frequently have
visceral involvement, aggressive disease, and/or a risk of
rapid deterioration, these data also support the decision
to treat our patient with nab-paclitaxel. Moreover, if
confirmed in prospectively designed clinical studies,
these findings would suggest that nab-paclitaxel shows
considerable clinical activity in virulent MBC and may be
preferentially selected to treat patients with more
aggressive tumor characteristics.
Nab-paclitaxel therefore appears to be an effective
treatment for many patients with MBC, and may be
preferred for patients with characteristics of aggressive
disease, including those with mTNBC. Further trials to
explore this theory are ongoing. For example, the Phase
II/III tnAcity trial is evaluating nab-paclitaxel in combi-
nation with carboplatin or gemcitabine versus carboplatin
plus gemcitabine in patients with mTNBC [27]. SNAP
(Schedules of Nab-Paclitaxel in Metastatic Breast
Cancer) [28] is evaluating induction therapy with three
cycles of high-dose weekly nab-paclitaxel, followed by
different maintenance therapy doses in women with
HER2 negative and ER negative or ER positive/refrac-
tory MBC. Findings from SNAP could also lead to the
introduction of alternative nab-paclitaxel dosing sche-
dules, which could allow physicians to tailor the use of
this agent according to individual patient needs since
balancing efficacy and safety is a key goal for delivering a
positive risk–benefit profile for each patient.
Conclusion
Nab-paclitaxel can safely be offered to many women with
MBC, with reasonable expectations of clinical benefit
and without concern of significant toxicity. Moreover,
nab-paclitaxel may be particularly beneficial for patients
with aggressive disease, including those with mTNBC.
Thus, nab-paclitaxel 260mg/m2 Q3W is an effective
treatment for MBC and a welcome addition to the
treatment armamentarium. Ongoing research to evaluate
different dosing schedules and combination regimens of
nab-paclitaxel could broaden the clinical utility of this
agent in the future.
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